Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025855 | 1.00 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP4F2CYP4A11 | |
| SCHEMBL20330026 | 0.86 | SLC6A4 (0.33) | CYP4F2CYP4A11SLC6A2 | |
| SCHEMBL21421631 | 0.86 | SLC6A4 (0.33) | CYP4F2CYP4A11SLC6A2 | |
| SCHEMBL21907822 | 0.86 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL20330464 | 0.82 | GCK (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL20324945 | 0.82 | IAPP (0.36) | ADRB2ADRB1ADRB3CYP4F2CYP4A11 | |
| SCHEMBL20326096 | 0.82 | IAPP (0.36) | ADRB2ADRB1ADRB3CYP4F2CYP4A11 | |
| SCHEMBL21673566 | 0.81 | ADRB2 (0.38) | ADRB2ADRB1ADRB3 | |
| SCHEMBL20324946 | 0.81 | ADRB2 (0.38) | ADRB2ADRB1ADRB3 | |
| SCHEMBL20046523 | 0.80 | CYP4F2 (0.30) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | ADRB2 4182/4885ADRB1 4656/4885ADRB3 4546/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | ADRB2 4600/4885ADRB1 4691/4885ADRB3 4725/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | ADRB2 4584/4885ADRB1 4547/4885ADRB3 4582/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | ADRB2 4600/4885ADRB1 4691/4885ADRB3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.